Unveiling 7 Analyst Insights On Avidity Biosciences
Portfolio Pulse from Benzinga Insights
Avidity Biosciences (NASDAQ:RNA) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. The average 12-month price target has increased to $68.86. Despite challenges like a decline in revenue and low net margins, the company shows strong ROE and low debt dependency.
September 16, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avidity Biosciences has received a mix of analyst ratings, with a majority being somewhat bullish. The average 12-month price target has increased to $68.86, indicating positive sentiment. However, the company faces challenges with declining revenue and low net margins.
The majority of analysts are somewhat bullish on Avidity Biosciences, with an increase in the average price target suggesting positive sentiment. Despite revenue and margin challenges, the company's strong ROE and low debt levels are positive indicators.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100